Ascendis Pharma A (ASND) Non-Current Deferred Tax Liability (2014 - 2025)

Ascendis Pharma A has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $11.2 million in Q4 2025.

• Quarterly Non-Current Deferred Tax Liability rose 44.43% year-over-year to $11.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.2 million (up 44.43% YoY) and the FY2025 annual result came in at $11.2 million, up 44.43% from the prior year.
• Non-Current Deferred Tax Liability slipped to $11.2 million in Q4 2025 per ASND's latest filing, from $12.0 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $12.0 million in Q3 2025 and troughed at $6.3 million in Q4 2023.
• A 3-year average of $9.1 million and a median of $8.2 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• The widest YoY moves for Non-Current Deferred Tax Liability: up 44.43% in 2025, down 5.68% in 2025.
• Over 3 years, Non-Current Deferred Tax Liability stood at $6.3 million in 2023, then increased by 23.64% to $7.8 million in 2024, then surged by 44.43% to $11.2 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $11.2 million, $12.0 million, and $10.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.